Astria Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis
Astria Therapeutics is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215 (navenib...
Get the Latest Astria Therapeutics, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeAstria Therapeutics, Inc. Overview
Pro stress-test →Astria Therapeutics is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215 (navenibart), is a monoclonal antibody inhibitor of plasma kallikrein in late-stage development for hereditary angioedema (HAE).
Strategic Profile
Pro stress-test →The acquisition strengthens BioCryst's position as a leader in hereditary angioedema and enhances long-term growth trajectory. Navenibart is a late-stage, long-acting plasma kallikrein inhibitor currently in Phase 3 clinical development with potential to be the first HAE therapy with every-three and every-six month dosing.
Competitive Landscape
Pro stress-test →Astria competed in the rare disease biopharmaceutical space, specifically in hereditary angioedema therapies. Prior to acquisition, navenibart competed against existing HAE treatments including established plasma kallikrein inhibitors and other HAE therapies. BioCryst's acquisition reflects the strategic value of this late-stage asset in a growing HAE treatment market.
Industry Context
Astria Therapeutics, Inc. operates in Pharmaceuticals.
Key facts
Founded: 2008 · Headquarters: Boston, MA · Revenue: Pre-commercial (no product revenue; development-stage company)